Clinical trial
Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
NCT02883556 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 27, 2017
- Completion date
- December 15, 2020
- Enrollment
- 57 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.